AltraBio propose un accompagnement biostatistique complet pour les études cliniques, les études observationnelles et les projets basés sur des données de vie réelle (RWE). Présents dans de nombreuses aires thérapeutiques — notamment les neurosciences, l’immunologie, l’oncologie, la dermatologie, la cardiologie et la rhumato-pneumologie —, nos biostatisticiens expérimentés soutiennent les acteurs de la santé (biopharma humaine et vétérinaire, dispositifs médicaux, biotechs et CHU) des phases de conception jusqu’au suivi clinique post-commercialisation.
Un accompagnement biostatistique complet pour la recherche clinique
Conception de l’étude & planification biostatistique
Détermination précise de la taille d’échantillon nécessaire pour garantir la validité scientifique de vos résultats et répondre aux exigences réglementaires.
Rédaction méthodologique claire du synopsis et des protocoles d’études cliniques.
Structuration détaillée de la méthodologie analytique, des critères d’évaluation principaux et secondaires avant le gel de la base de données.
Gestion des données & conformité réglementaire (CDISC)
Rédaction et structuration des processus de collecte, de contrôle qualité et de gouvernance des données.
Choix et paramétrage des outils de cahier d’observation électronique adaptés à votre design d’étude.
Extraction, mise en forme et mise en conformité de vos jeux de données selon les standards internationaux CDISC.
Traitement des valeurs aberrantes, des déviations au protocole et imputation statistique validée des données manquantes.
Analyse statistique, modélisation & valorisation
Analyses d’inférence statistique (paramétriques et non paramétriques) pour évaluer la sécurité et l’efficacité de vos traitements.
Construction de modèles de régression multivariée et d’apprentissage automatique pour identifier des facteurs pronostiques et stratifier les populations de patients.
Livrables statistiques complets (PDF et tableaux de bord web interactifs) intégrant la traçabilité des algorithmes de traitement.
Assistance à la rédaction d’abstracts, de posters et d’articles scientifiques pour la publication dans des revues à comité de lecture.
Publications scientifiques et médicales
2026
Randall, Matthew J.; Andersen, Claus A.; Brown, Kevin K.; de Bernard, Simon; Ford, Paul; Kaminski, Naftali; Kreuter, Michael; Lim, Sharlene; Maher, Toby M.; Prasad, Niyati; Prasse, Antje; Pujuguet, Philippe; Teneggi, Vincenzo; van den Blink, Bernt; Wain, Louise V.; Watkins, Timothy R.; Wuyts, Wim; Bauer, Yasmina
Prognostic biomarkers for idiopathic pulmonary fibrosis: findings from ISABELA clinical trials Article de journal
Dans: ERJ Open Res, vol. 12, no. 1, p. 00893–2025, 2026, ISSN: 2312-0541.
@article{Randall2025,
title = {Prognostic biomarkers for idiopathic pulmonary fibrosis: findings from ISABELA clinical trials},
author = {Matthew J. Randall and Claus A. Andersen and Kevin K. Brown and Simon de Bernard and Paul Ford and Naftali Kaminski and Michael Kreuter and Sharlene Lim and Toby M. Maher and Niyati Prasad and Antje Prasse and Philippe Pujuguet and Vincenzo Teneggi and Bernt van den Blink and Louise V. Wain and Timothy R. Watkins and Wim Wuyts and Yasmina Bauer},
doi = {10.1183/23120541.00893-2025},
issn = {2312-0541},
year = {2026},
date = {2026-01-00},
urldate = {2026-01-00},
journal = {ERJ Open Res},
volume = {12},
number = {1},
pages = {00893--2025},
publisher = {European Respiratory Society (ERS)},
abstract = {Background
Idiopathic pulmonary fibrosis (IPF) is characterised by progressive loss of pulmonary function and poor survival. Although biomarkers for disease progression and mortality exist, their reliability in large studies remains unproven. This study investigates prognostic biomarkers from the ISABELA trials, the largest IPF cohort to date, to identify those predicting worse clinical outcomes.
Methods
Plasma from 1280 IPF patients in ISABELA 1 and 2 (NCT03711162, NCT03733444) was analysed for 17 circulating soluble disease-related biomarkers at multiple time-points and for the MUC5B (rs35705950_T) genotype. Statistical learning algorithms investigated biomarker levels/status with disease progression (≥10% decline in forced vital capacity (FVC) or mortality within 1 year) and pharmacotherapy.
Results
Patients with ≥10% annual decline in FVC had higher median baseline of matrix metalloproteinase-7 (MMP-7) versus those with <10% decline (5.5 versus 4.2 µg·L−1; p<0.005). Patients with baseline MMP-7 ≥5.2 μg·L−1 and/or C-C motif chemokine ligand 18 (CCL18) ≥75.2 μg·L−1 had increased risk of mortality (p<0.0001); with patients having both elevated biomarkers at an even greater risk. Machine learning identified CCL18 changes by week 26 as a predictor of disease progression. The rs35705950_T genotype predicted neither mortality nor disease progression.
Conclusions
We provide new insights into the prognostic value of MMP-7 and CCL18 in identifying high-risk IPF patients in the largest cohort to date. The combination of high baseline MMP-7 and CCL18 levels, along with longitudinal changes in CCL18, has the potential to enhance risk stratification and support efficacy assessment and monitoring in clinical trials.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Idiopathic pulmonary fibrosis (IPF) is characterised by progressive loss of pulmonary function and poor survival. Although biomarkers for disease progression and mortality exist, their reliability in large studies remains unproven. This study investigates prognostic biomarkers from the ISABELA trials, the largest IPF cohort to date, to identify those predicting worse clinical outcomes.
Methods
Plasma from 1280 IPF patients in ISABELA 1 and 2 (NCT03711162, NCT03733444) was analysed for 17 circulating soluble disease-related biomarkers at multiple time-points and for the MUC5B (rs35705950_T) genotype. Statistical learning algorithms investigated biomarker levels/status with disease progression (≥10% decline in forced vital capacity (FVC) or mortality within 1 year) and pharmacotherapy.
Results
Patients with ≥10% annual decline in FVC had higher median baseline of matrix metalloproteinase-7 (MMP-7) versus those with <10% decline (5.5 versus 4.2 µg·L−1; p<0.005). Patients with baseline MMP-7 ≥5.2 μg·L−1 and/or C-C motif chemokine ligand 18 (CCL18) ≥75.2 μg·L−1 had increased risk of mortality (p<0.0001); with patients having both elevated biomarkers at an even greater risk. Machine learning identified CCL18 changes by week 26 as a predictor of disease progression. The rs35705950_T genotype predicted neither mortality nor disease progression.
Conclusions
We provide new insights into the prognostic value of MMP-7 and CCL18 in identifying high-risk IPF patients in the largest cohort to date. The combination of high baseline MMP-7 and CCL18 levels, along with longitudinal changes in CCL18, has the potential to enhance risk stratification and support efficacy assessment and monitoring in clinical trials.
2025
Cognasse, Fabrice; Nguyen, Kim Anh; Heestermans, Marco; Arthaud, Charles-Antoine; Eyraud, Marie-Ange; Prier, Amelie; de Bernard, Simon; Nourikyan, Julien; Duchez, Anne-Claire; Avril, Stephane; Garraud, Olivier; Hamzeh-Cognasse, Hind
Computational modeling of platelet activation signatures in response to diverse immune and hemostatic agonists Article de journal
Dans: Platelets, vol. 36, no. 1, 2025, ISSN: 1369-1635.
@article{Cognasse2025,
title = {Computational modeling of platelet activation signatures in response to diverse immune and hemostatic agonists},
author = {Fabrice Cognasse and Kim Anh Nguyen and Marco Heestermans and Charles-Antoine Arthaud and Marie-Ange Eyraud and Amelie Prier and Simon de Bernard and Julien Nourikyan and Anne-Claire Duchez and Stephane Avril and Olivier Garraud and Hind Hamzeh-Cognasse},
doi = {10.1080/09537104.2025.2572982},
issn = {1369-1635},
year = {2025},
date = {2025-10-27},
urldate = {2025-10-27},
journal = {Platelets},
volume = {36},
number = {1},
publisher = {Informa UK Limited},
abstract = {Platelets are increasingly recognized as key players not only in hemostasis, but also in immunity and inflammation. However, the mechanisms and markers underlying their activation remain incompletely understood. This study aimed to decipher how platelets respond to different stimuli and to identify specific molecular signatures using computational approaches. Platelets from 10 healthy donors were stimulated under seven conditions, including TRAP (PAR-1), AYPGKF (PAR-4), ADP, collagen, sCD40L, fibrinogen, and a control. A total of 47 markers—encompassing membrane proteins, soluble mediators, and intracellular signals—were analyzed. Statistical and machine learning methods, including hierarchical clustering and random forest algorithms, were used to classify and interpret the data. Distinct activation profiles emerged for each agonist. A reduced panel of six markers (AKT, CD40L, CD62P, PKC, RANTES, and TSLP) enabled identification of the stimulus with 86.8% accuracy. Machine learning further improved classification (87.9% multiclass accuracy). Differences were also observed across donors, highlighting inter-individual variability. This work supports a new paradigm in which platelets act as “biological sensors,” fine-tuning their responses to environmental cues. The identified biomarker panel provides a basis for further investigation into the characterization of platelet activation profiles, with potential relevance for future diagnostic and therapeutic applications in thromboinflammatory and immune-mediated conditions.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Ribeiro, Sara; Alves, Karine; Nourikyan, Julien; Lavergne, Jean-Pierre; de Bernard, Simon; Buffat, Laurent
Identifying potential novel widespread determinants of bacterial pathogenicity using phylogenetic-based orthology analysis Article de journal
Dans: Front. Microbiol., vol. 16, 2025, ISSN: 1664-302X.
@article{Ribeiro2025,
title = {Identifying potential novel widespread determinants of bacterial pathogenicity using phylogenetic-based orthology analysis},
author = {Sara Ribeiro and Karine Alves and Julien Nourikyan and Jean-Pierre Lavergne and Simon de Bernard and Laurent Buffat},
doi = {10.3389/fmicb.2025.1494490},
issn = {1664-302X},
year = {2025},
date = {2025-05-01},
urldate = {2025-05-01},
journal = {Front. Microbiol.},
volume = {16},
publisher = {Frontiers Media SA},
abstract = {<jats:sec><jats:title>Introduction</jats:title><jats:p>The global rise in antibiotic resistance and emergence of new bacterial pathogens pose a significant threat to public health. Novel approaches to uncover potential novel diagnostic and therapeutic targets for these pathogens are needed.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>In this study, we conducted a large-scale, phylogenetic-based orthology analysis (OA) to compare the proteomes of pathogenic to humans (HP) and non-pathogenic to humans (NHP) bacterial strains across 734 strains from 514 species and 91 families.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Using a dedicated workflow, we identified 4,383 hierarchical orthologous groups (HOGs) significantly associated with the HP label, many of which are linked to critical factors such as stress tolerance, metabolic versatility, and antibiotic resistance. Both known virulence factors (VFs) and potential novel widespread pathogenicity determinants were uncovered, supported by both statistical testing and complementary protein domain analysis.</jats:p></jats:sec><jats:sec><jats:title>Discussion</jats:title><jats:p>By integrating curated strain-level pathogenicity annotations from BacSPaD with phylogeny-based OA, we introduce a novel approach and provide a novel resource for bacterial pathogenicity research.</jats:p></jats:sec>},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
